Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review

By Dailey George  

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 2007-2014

Informa Healthcare

Access to resources Recommend Favorite

Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal–bolus regimens: insights from the PREDICTIVE study

By Hermansen Kjeld   Dornhorst Anne   Sreenan Seamus  

Current Medical Research and Opinion, Vol. 25, Iss. 11, 2009-11 ,pp. : 2601-2608

Informa Healthcare

Access to resources Recommend Favorite

Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin

By McAdam-Marx Carrie   Yu Junhua   Bouchard Jonathan   Aagren Mark   Brixner Diana I.  

Current Medical Research and Opinion, Vol. 26, Iss. 1, 2010-01 ,pp. : 191-201

Informa Healthcare

Access to resources Recommend Favorite

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 936-948

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 936-948

John Wiley & Sons Inc

Access to resources Recommend Favorite